Truist Financial Raises Quest Diagnostics (NYSE:DGX) Price Target to $158.00

Quest Diagnostics (NYSE:DGX) had its price target hoisted by stock analysts at Truist Financial from $150.00 to $158.00 in a research note issued on Monday, Benzinga reports. The brokerage presently has a “hold” rating on the medical research company’s stock. Truist Financial’s target price would suggest a potential upside of 9.09% from the stock’s current price.

A number of other brokerages have also commented on DGX. JPMorgan Chase & Co. increased their price objective on Quest Diagnostics from $152.00 to $155.00 and gave the company a “neutral” rating in a research report on Thursday, May 30th. Barclays boosted their price objective on shares of Quest Diagnostics from $138.00 to $144.00 and gave the company an “equal weight” rating in a report on Thursday, April 25th. Robert W. Baird upped their target price on shares of Quest Diagnostics from $145.00 to $153.00 and gave the company a “neutral” rating in a research note on Friday, July 5th. Mizuho lifted their price target on shares of Quest Diagnostics from $150.00 to $155.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Finally, StockNews.com upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Wednesday, July 10th. Nine investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $149.31.

Quest Diagnostics Price Performance

Shares of NYSE:DGX traded up $0.72 during midday trading on Monday, reaching $144.83. The company’s stock had a trading volume of 66,263 shares, compared to its average volume of 974,950. The business’s fifty day simple moving average is $139.84 and its 200-day simple moving average is $134.02. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.97 and a quick ratio of 0.89. Quest Diagnostics has a fifty-two week low of $119.59 and a fifty-two week high of $145.62. The company has a market capitalization of $16.09 billion, a P/E ratio of 19.49, a P/E/G ratio of 3.13 and a beta of 0.89.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Tuesday, April 23rd. The medical research company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.86 by $0.18. Quest Diagnostics had a net margin of 9.11% and a return on equity of 15.52%. The company had revenue of $2.37 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same period in the previous year, the firm posted $2.04 earnings per share. The company’s revenue was up 1.7% on a year-over-year basis. As a group, equities research analysts expect that Quest Diagnostics will post 8.79 EPS for the current fiscal year.

Insider Activity at Quest Diagnostics

In other Quest Diagnostics news, SVP Karthik Kuppusamy sold 1,760 shares of the business’s stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of $140.00, for a total transaction of $246,400.00. Following the transaction, the senior vice president now owns 13,435 shares of the company’s stock, valued at $1,880,900. The sale was disclosed in a document filed with the SEC, which is available through this link. 0.79% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Altshuler Shaham Ltd bought a new position in Quest Diagnostics during the fourth quarter worth $26,000. BKM Wealth Management LLC bought a new stake in shares of Quest Diagnostics during the 4th quarter worth about $29,000. Spartan Planning & Wealth Management acquired a new position in Quest Diagnostics in the 4th quarter valued at about $31,000. Alaska Permanent Fund Corp raised its holdings in Quest Diagnostics by 79.3% in the 4th quarter. Alaska Permanent Fund Corp now owns 242 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 107 shares during the period. Finally, Riverview Trust Co acquired a new stake in Quest Diagnostics during the first quarter worth approximately $33,000. 88.06% of the stock is owned by institutional investors and hedge funds.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.